More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Wednesday's Economic News Crunch Could Tilt Markets
- Obama Reiterates Commitment to Boost US-India Ties
- NBA D-League On The Rise
- Australia Wheat Exporters Face Challenges: GrainCorp
- Japan Export Rebound Eases Fear of New Recession
- Starbucks Eyes China as Next Major Market
- Stifling Anger at Work Can Kill, Survey Finds
- The Social Media Gaming Threat
- Why You Should Play the Reflation Trade: Stock Picker
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Facebook's Biggest-Ever Holiday Shopping Season
- Facebook's New Dual Class Structure - Slow Steps to an IPO
- 5 Big Bank Stocks Investors Should Consider: Strategists
- Gambling Drunk, Texting to Live And America's On Sale - Your Emails
- Nov. 24: Unusual Volume Leaders
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Deere Reports Quarterly Net Loss, Revenue Falls
- Tiffany Profit Higher Than Expected; Raises Outlook
- Americans Ditch Planes for Trains this Thanksgiving
- Obama Reiterates Commitment to Boost US-India Ties
- FDIC's Bair Cautions on Risks in Bank Break-Up Plan
- Call Me Crazy: Confessions of a Black Friday Shopper
- Turkey Day 101: How Well Do You Know Your Bird?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
A presumably one-episode character on the show has just been told she has cancer that has spread. Soon after her friend or sister, who wants the woman to put up a fight, chimes in with--and I'm paraphrasing because I couldn't get the show to play on my desktop, but this is pretty darn close--"There's a clinical trial where they're combining Avastin with chemo."
The character even correctly pronounced Avastin. Product placement--even verbal--is commonplace in network TV shows these days. But I can't recall a specific cancer drug being singled out by name in a drama or sitcom. And it might not be an example of formal product placement. Maybe one of the scriptwriters or medical consultants on the show just threw it in there for authenticity. After all, DNA does not do branded, direct-to-consumer advertising of its oncology products.
And just so this post isn't entirely frivolous, Genentech [
Loading...
()
]happens to report its third quarter earnings tomorrow after the closing bell. And, as always, Avastin sales are key. The Street expects revenue from the drug to come in around $760 million. But some analysts are forecasting a miss. In a research note to clients this morning, Bill Tanner at Leerink Swann writes, "Our estimate of $707 (million) reflects greater caution as to uptake in the (lung) and breast indications."
And in a conference call with clients and reporters last week, Deutsche Bank's Mark Schoenbaum, who predicts Avastin Q3 numbers of $744 million, said, "Breast cancer is where we think investor focus is now. It'll be important to listen (on the Genentech conference call) if sales are flat or disappointing. There will be a lot of questions about penetrating into breast. Anything less (than last quarter's 35 percent penetration) or flat will be disappointing. That's the most important single metric." Leerink may trade in DNA. DB makes a market in DNA and wants to bank the company.
In big cap biotech beaten down shares of Genentech, at least in the very early going, are the biggest dollar gainer in the sector this morning. Investors, perhaps, are making a commitment. If only Meredith and Derek could do the same.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes